Athira Pharma to Attend May 2024 Conferences

BOTHELL, Wash., May 02, 2024 – Athira Pharma, Inc. (NASDAQ: ATHA), a biopharmaceutical company in the late stages of clinical development, is dedicated to creating small molecule therapies aimed at rejuvenating neuronal health and mitigating neurodegeneration. The company recently announced its participation in several investor conferences this May.

Athira's schedule includes the Sidoti May 2024 Virtual Investor Conference, where they will deliver a company presentation on Wednesday, May 8, 2024, from 10:45 a.m. to 11:15 a.m. ET. This will be held virtually. Additionally, Athira will take part in The Citizens JMP Life Sciences Conference via a fireside chat on Monday, May 13, 2024, from 1:30 p.m. to 1:55 p.m. ET at the New York Hilton Midtown.

Those interested can view live webcasts of these events through the Investors section on Athira’s website. Recorded replays of the webcasts will be available for at least 30 days after the events.

About Athira Pharma, Inc.

Based in the Seattle area, Athira Pharma, Inc. specializes in late-stage clinical biopharmaceutical developments. Their primary focus is on creating small molecules that enhance neuronal health and slow down neurodegenerative processes. Athira is committed to changing the trajectory of neurological diseases through innovative therapies that target the neurotrophic HGF system. One of their leading candidates, fosgonimeton, is currently under investigation in the Phase 2/3 LIFT-AD trial as a potential treatment for mild-to-moderate Alzheimer’s disease. The trial is expected to produce topline data in the latter half of 2024.

This focus on groundbreaking treatments positions Athira as a key player in the field of neurodegeneration, with the potential to bring significant advancements in the management of neurological conditions.